rs137852972
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM1PM2PP5_Very_Strong
The NM_001122955.4(BSCL2):c.455A>G(p.Asn152Ser) variant causes a missense change. The variant allele was found at a frequency of 0.00000958 in 1,460,780 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: not found (cov: 31)
Exomes 𝑓: 0.0000096 ( 0 hom. )
Consequence
BSCL2
NM_001122955.4 missense
NM_001122955.4 missense
Scores
3
10
6
Clinical Significance
Conservation
PhyloP100: 6.41
Genes affected
BSCL2 (HGNC:15832): (BSCL2 lipid droplet biogenesis associated, seipin) This gene encodes the multi-pass transmembrane protein protein seipin. This protein localizes to the endoplasmic reticulum and may be important for lipid droplet morphology. Mutations in this gene have been associated with congenital generalized lipodystrophy type 2 or Berardinelli-Seip syndrome, a rare autosomal recessive disease characterized by a near absence of adipose tissue and severe insulin resistance. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. Naturally occurring read-through transcription occurs between this locus and the neighboring locus HNRNPUL2 (heterogeneous nuclear ribonucleoprotein U-like 2).[provided by RefSeq, Mar 2011]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PM1
In a topological_domain Lumenal (size 194) in uniprot entity BSCL2_HUMAN there are 12 pathogenic changes around while only 0 benign (100%) in NM_001122955.4
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 11-62702499-T-C is Pathogenic according to our data. Variant chr11-62702499-T-C is described in ClinVar as [Pathogenic]. Clinvar id is 4543.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr11-62702499-T-C is described in Lovd as [Pathogenic]. Variant chr11-62702499-T-C is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BSCL2 | NM_001122955.4 | c.455A>G | p.Asn152Ser | missense_variant | 3/11 | ENST00000360796.10 | NP_001116427.1 | |
HNRNPUL2-BSCL2 | NR_037946.1 | n.2975A>G | non_coding_transcript_exon_variant | 16/24 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BSCL2 | ENST00000360796.10 | c.455A>G | p.Asn152Ser | missense_variant | 3/11 | 1 | NM_001122955.4 | ENSP00000354032 | A2 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD3 genomes
Cov.:
31
GnomAD3 exomes AF: 0.0000159 AC: 4AN: 251364Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135872
GnomAD3 exomes
AF:
AC:
4
AN:
251364
Hom.:
AF XY:
AC XY:
2
AN XY:
135872
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000958 AC: 14AN: 1460780Hom.: 0 Cov.: 31 AF XY: 0.0000124 AC XY: 9AN XY: 726720
GnomAD4 exome
AF:
AC:
14
AN:
1460780
Hom.:
Cov.:
31
AF XY:
AC XY:
9
AN XY:
726720
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 31
GnomAD4 genome
Cov.:
31
Bravo
AF:
ExAC
AF:
AC:
1
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:21Uncertain:1Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:7
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Mar 01, 2023 | BSCL2: PP1:Strong, PM2, PS4:Moderate, PP4, PS3:Supporting - |
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Aug 17, 2015 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics, Academic Medical Center | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 29, 2023 | Published functional studies demonstrate protein over-expression and impairment of synaptic neurotransmission (Windpassinger et al., 2004; Wei et al., 2014); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 17387721, 21750110, 22045697, 21957196, 18585921, 14981520, 18612770, 24345054, 16427281, 23553728, 19396477, 31589614, 31211173, 27549087, 29269637, 25219579, 27738760, 25454168, 20598714, 34085946, 32320108, 15732094) - |
Pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Oct 23, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | Jun 09, 2022 | - - |
Hereditary spastic paraplegia 17 Pathogenic:4Other:1
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jun 01, 2013 | - - |
Pathogenic, criteria provided, single submitter | curation | SIB Swiss Institute of Bioinformatics | May 31, 2018 | This variant is interpreted as a Pathogenic, for Spastic paraplegia 17, autosomal dominant, in Autosomal Dominant manner. The following ACMG Tag(s) were applied: PS4 => Prevalence in affecteds statistically increased over controls. N88S is the most frequent mutation. According to Ito & Suzuki 2009, 40 patients out of 48 patients from 16 families have N88S. In ExAC: 1 individual with N88S out of 60000 (PMID:18790819). PS3 => Well-established functional studies show a deleterious effect (PMID:17387721) (PMID:21750110). - |
Pathogenic, criteria provided, single submitter | clinical testing | Paris Brain Institute, Inserm - ICM | - | - - |
Pathogenic, criteria provided, single submitter | research | Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL) | Apr 27, 2023 | - - |
Neuronopathy, distal hereditary motor, type 5C Pathogenic:3
Pathogenic, no assertion criteria provided | literature only | OMIM | Jun 01, 2013 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | MGZ Medical Genetics Center | Jun 17, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics Munich, Klinikum Rechts Der Isar, TU München | Apr 30, 2021 | - - |
Neuronopathy, distal hereditary motor, type 5A Pathogenic:2
Pathogenic, no assertion criteria provided | literature only | Northcott Neuroscience Laboratory, ANZAC Research Institute | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Equipe Genetique des Anomalies du Developpement, Université de Bourgogne | Oct 09, 2018 | - - |
not specified Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Sep 19, 2016 | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 06, 2023 | The c.263A>G (p.N88S) alteration is located in exon 3 (coding exon 2) of the BSCL2 gene. This alteration results from an A to G substitution at nucleotide position 263, causing the asparagine (N) at amino acid position 88 to be replaced by a serine (S)._x000D_ _x000D_ Based on the available evidence, the BSCL2 c.263A>G (p.N88S) alteration is classified as pathogenic for autosomal dominant BSCL2-related neurologic disorder; however, its clinical significance for autosomal recessive BSCL2-related syndrome is unclear. Based on data from gnomAD, the G allele has an overall frequency of 0.002% (4/251364) total alleles studied. The highest observed frequency was 0.01% (1/10074) of Ashkenazi Jewish alleles. This variant has been reported in multiple individuals with features of autosomal dominant BSCL2-related neurologic disorder and cosegregates with disease in multiple families (Thomas, 2022; Gentile, 2021; Fernández-Eulate, 2020; Minami, 2018; Musacchio, 2017; Ollivier, 2015; Monteiro, 2015; Rakoevi-Stojanovi, 2010; Brusse, 2009; Cafforio, 2008; van de Warrenburg, 2006; Auer-Grumbach, 2005; Windpassinger, 2004). This amino acid position is highly conserved in available vertebrate species. In vitro and in vivo functional studies demonstrate that this alteration disrupts the N-glycosylation site of seipin resulting in protein misfolding and accumulation consistent with a toxic gain-of-function effect (Lundin, 2006; Ito, 2007; Windpassinger, 2004; Ito, 2008; Fei, 2011; Yagi, 2011; Ito, 2012). Additional functional studies show aberrant neuronal electrophysiology and synaptic plasticity in vitro (Wei, 2014). This alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic. - |
Peripheral neuropathy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Kariminejad - Najmabadi Pathology & Genetics Center | Jul 10, 2021 | - - |
Hereditary spastic paraplegia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Genome Diagnostics Laboratory, The Hospital for Sick Children | Sep 24, 2020 | - - |
Charcot-Marie-Tooth disease type 2 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 14, 2023 | This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 88 of the BSCL2 protein (p.Asn88Ser). This variant is present in population databases (rs137852972, gnomAD 0.01%). This missense change has been observed in individuals with autosomal dominant BSCL2-related conditions (PMID: 14981520, 15732094, 16427281, 20598714, 23553728, 25219579, 25454168). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 4543). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BSCL2 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects BSCL2 function (PMID: 14981520, 17387721, 18585921, 21957196, 22045697, 24345054). For these reasons, this variant has been classified as Pathogenic. - |
Berardinelli-Seip congenital lipodystrophy Uncertain:1
Uncertain significance, no assertion criteria provided | literature only | Inherited Neuropathy Consortium Ii, University Of Miami | Jan 06, 2016 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Pathogenic
.;.;.;D;D;D;.;D;D
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Pathogenic
D;D;D;.;.;D;D;D;D
M_CAP
Uncertain
D
MetaRNN
Uncertain
D;D;D;D;D;D;D;D;D
MetaSVM
Uncertain
D
MutationAssessor
Uncertain
.;M;.;M;M;M;.;.;.
MutationTaster
Benign
A;A;A;A;A;A;A
PrimateAI
Benign
T
PROVEAN
Uncertain
D;D;D;D;D;D;D;D;D
REVEL
Pathogenic
Sift
Benign
T;T;T;D;D;D;T;T;T
Sift4G
Uncertain
D;D;D;D;D;D;.;.;.
Polyphen
0.94, 1.0
.;P;.;D;D;D;.;.;.
Vest4
MutPred
0.62
.;Gain of disorder (P = 0.0519);.;Gain of disorder (P = 0.0519);Gain of disorder (P = 0.0519);Gain of disorder (P = 0.0519);Gain of disorder (P = 0.0519);.;Gain of disorder (P = 0.0519);
MVP
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at